Top

Published in:

01-10-2015 | Research Article

High peritumoral Bmi-1 expression is an independent prognosticator of poor prognosis in renal cell carcinoma

Authors: Qilai Long, Li Liu, Yu Xia, Qi Bai, Jiajun Wang, Jiejie Xu, Jianming Guo

Published in: Tumor Biology | Issue 10/2015

Abstract

B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) is a transcriptional repressor, which plays important roles in the development of cancers, but the function of Bmi-1 in kidney tumorigenesis and its prognostic values remain unclear. This study aims to investigate prognostic values of the intratumoral and peritumoral expression of Bmi-1 in patients with renal cell carcinoma. Expression of Bmi-1 was assessed by immunohistochemistry in specimens containing paired tumor and peritumoral renal tissue from 241 patients who had undergone curative nephrectomy at Zhongshan Hospital from 2005 to 2007. The association of Bmi-1 expression with clinical and pathological parameters and outcomes was investigated. Specific expression of Bmi-1 was found both in peritumoral and intratumoral tissues. High expression of Bmi-1 in peritumoral but not intratumoral is significantly associated with poor overall survival (OS) (P < 0.001) and relapse-free survival (RFS) (P = 0.003). Furthermore, Bmi-1 expression was identified as an independent prognostic factor for OS, and combination of peritumoral Bmi-1 and tumor node metastasis (TNM) stage had a better power to predict the patients’ death and disease recurrence. High peritumoral Bmi-1 expression can serve as an independent prognostic biomarker and could be a novel therapeutic target for renal cell carcinoma (RCC).

Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2014;2:61.PubMedPubMedCentral

Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–90.CrossRefPubMed

Stewart GD, O’Mahony FC, Powles T, Riddick AC, Harrison DJ, Faratian D. What can molecular pathology contribute to the management of renal cell carcinoma? Nat Rev Urol. 2011;8:255–65.CrossRefPubMed

Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol. 1999;161:381–6. discussion 386–387.CrossRefPubMed

Ficarra V, Galfano A, Mancini M, Martignoni G, Artibani W. TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol. 2007;8:554–8.CrossRefPubMed

Muller J, Verrijzer P. Biochemical mechanisms of gene regulation by polycomb group protein complexes. Curr Opin Genet Dev. 2009;19:150–8.CrossRefPubMed

Guney I, Wu S, Sedivy JM. Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). Proc Natl Acad Sci U S A. 2006;103:3645–50.CrossRefPubMedPubMedCentral

Silva J, Garcia JM, Pena C, Garcia V, Dominguez G, Suarez D, et al. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin Cancer Res: Off J Am Assoc Cancer Res. 2006;12:6929–36.CrossRef

Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 1991;65:753–63.CrossRefPubMed

10.

van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 1991;65:737–52.CrossRefPubMed

11.

Chiba T, Seki A, Aoki R, Ichikawa H, Negishi M, Miyagi S, et al. Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and -independent manners in mice. Hepatology. 2010;52:1111–23.CrossRefPubMed

12.

Yu CC, Lo WL, Chen YW, Huang PI, Hsu HS, Tseng LM, et al. Bmi-1 regulates snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells. J Oncol. 2011;2011.

13.

Jiang L, Li J, Song L. Bmi-1, stem cells and cancer. Acta Biochim Biophys Sin. 2009;41:527–34.CrossRefPubMed

14.

Silva J, Garcia V, Garcia JM, Pena C, Dominguez G, Diaz R, et al. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res: BCR. 2007;9:R55.CrossRefPubMedPubMedCentral

15.

Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A. Expression of polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia. 2007;21:1116–22.PubMed

16.

Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006;66:6225–32.CrossRefPubMed

17.

Breuer RH, Snijders PJ, Sutedja GT, Sewalt RG, Otte AP, Postmus PE, et al. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer. 2005;48:299–306.CrossRefPubMed

18.

Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 2004;203:217–24.CrossRefPubMed

19.

Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, et al. Prognostic value of EZH2 expression and activity in renal cell carcinoma: a prospective study. PLoS One. 2013;8, e81484.CrossRefPubMedPubMedCentral

20.

Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–63.CrossRefPubMed

21.

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed

22.

Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26:2707–16.CrossRef

23.

Detre S, Saclani Jotti G, Dowsett M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48:876–8.CrossRefPubMedPubMedCentral

24.

McAllister SS, Weinberg RA. Tumor-host interactions: a far-reaching relationship. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28:4022–8.CrossRef

25.

Qin ZK, Yang JA, Ye YL, Zhang X, Xu LH, Zhou FJ, et al. Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer. 2009;9:61.CrossRefPubMedPubMedCentral

26.

Wang H, Pan K, Zhang HK, Weng DS, Zhou J, Li JJ, et al. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:535–41.CrossRefPubMed

27.

Kozakowski N, Soleiman A, Pammer J. BMI-1 expression is inversely correlated with the grading of renal clear cell carcinoma. Pathol Oncol Res: POR. 2008;14:9–13.CrossRefPubMed

28.

Choi YJ, Choi YL, Cho EY, Shin YK, Sung KW, Hwang YK, et al. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res Treat. 2009;113:83–93.CrossRefPubMed

29.

Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397:164–8.CrossRefPubMed

30.

Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 2009;119:3626–36.CrossRefPubMedPubMedCentral

31.

Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J, Guo J: EZH2 promotes tumor cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. 2014.

32.

Du R, Xia L, Ning X, Liu L, Sun W, Huang C, et al. Hypoxia-induced Bmi1 promotes renal tubular epithelial cell-mesenchymal transition and renal fibrosis via PI3K/Akt signal. Mol Biol Cell. 2014;25:2650–9.CrossRefPubMedPubMedCentral

33.

Blackledge NP, Farcas AM, Kondo T, King HW, McGouran JF, Hanssen LL, et al. Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and polycomb domain formation. Cell. 2014;157:1445–59.CrossRefPubMedPubMedCentral

34.

Bommi PV, Dimri M, Sahasrabuddhe AA, Khandekar J, Dimri GP. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle. 2010;9:2663–73.CrossRefPubMedPubMedCentral

35.

Wu J, Hu D, Yang G, Zhou J, Yang C, Gao Y, et al. Down-regulation of BMI-1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells. J Cell Biochem. 2011;112:1938–48.CrossRefPubMed

Title: High peritumoral Bmi-1 expression is an independent prognosticator of poor prognosis in renal cell carcinoma
Authors: Qilai Long
Li Liu
Yu Xia
Qi Bai
Jiajun Wang
Jiejie Xu
Jianming Guo
Publication date: 01-10-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 10/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3525-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2015

A combinatory use of adenoviruses expressing melanoma differentiation-associated gene-7 and replication-competent adenoviruses produces synergistic effects on pancreatic carcinoma cells

Transcriptome analysis of the cancer/testis genes, DAZ1, AURKC, and TEX101, in breast tumors and six breast cancer cell lines

Cell injury, retrodifferentiation and the cancer treatment paradox

Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients

Gene mutations in gastric cancer: a review of recent next-generation sequencing studies

MiR-371-373 cluster acts as a tumor-suppressor-miR and promotes cell cycle arrest in unrestricted somatic stem cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer